Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849402 · ClinicalTrials.gov registry record · NA
Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder
A NA study of Treatment-Resistant Depression and Bipolar II Disorder, Most Recent Episode Major Depressive, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05849402 is a NA study of Treatment-Resistant Depression and Bipolar II Disorder, Most Recent Episode Major Depressive that is actively recruiting participants, run by Stanford University. The registered enrollment target is 60 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05849402, a NA study of Treatment-Resistant Depression and Bipolar II Disorder, Most Recent Episode Major Depressive, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effectiveness of accelerated intermittent theta-burst transcranial magnetic stimulation (aiTBS) in inducing anti-depressant responses in individuals with treatment-resistant depression of bipolar II disorder. This is a double-blind, randomized, sham-controlled trial that targets a single location on the left dorsolateral prefrontal cortex (LDLPFC) using the MagPro rTMS system.
Conditions Studied
Interventions
- DEVICE Active Comparator: Active aiTBS
- DEVICE Sham Comparator: Sham aiTBS
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2026-07-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05849402
The ClinicalTrials.gov registry entry for NCT05849402 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (84% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Active Comparator: Active aiTBS is the first listed.
NCT05849402 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05849402 about?
NCT05849402 is a clinical study titled "Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder". The purpose of this study is to investigate the effectiveness of accelerated intermittent theta-burst transcranial magnetic stimulation (aiTBS) in inducing anti-depressant responses in individuals with treatment-resistant depression of bipolar II disorder. This is a double-blind, randomized, sham-co...
What is the current status of trial NCT05849402?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2022-12-20. Estimated completion is 2026-07-30.
What conditions does trial NCT05849402 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression, Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode.
What interventions are being tested in trial NCT05849402?
The interventions under investigation include: Active Comparator: Active aiTBS (DEVICE), Sham Comparator: Sham aiTBS (DEVICE).
Who is sponsoring clinical trial NCT05849402?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849402 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
RECRUITING · NA
-
DBS for TRD With the Medtronic Percept PC
RECRUITING · NA
-
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
RECRUITING · NA
-
PCS in Severe Treatment Resistant Depression
RECRUITING · NA
-
Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression
RECRUITING · NA
Explore more on PlainTrial
Treatment-Resistant Depression
All registered trials for this condition
Bipolar II Disorder, Most Recent Episode Major Depressive
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.